It is critical for US biotech companies to understand the needs of European payers

17th October 2013
There is increasing divergence between the evidence regulators need for approval, and that needed by payers for reimbursement. Whilst ignoring the needs of European payers before entering Phase 3...
Learn More

Is Manufacturing just ‘bad news’?

15th August 2013
Over the past few months one could have been forgiven for thinking that outsourcing supply to Indian manufacturers was a major problem. The recent spate of FDA Warning Letters, and actions, against...
Learn More

A genome's got to know it's limitations

28th January 2013
The UK Government has become the latest believer in the genome. In December 2012, the prime minister of the United Kingdom announced an ambitious plan to fully sequence the genomes of 100,000 Britons...
Learn More

Biotech in Israel: A Land of Promise

18th May 2012
Israeli medtech is widely regarded as world-class both by investors and the industry at large. Israeli biotech, on the other hand, does not (yet) enjoy similar standing. True, there are some notable...
Learn More

FDA Approvals Provide Reason For Cheer

14th March 2012
Both biotech and pharma investors are in despair. KPMG recently concluded that returns on R&D investment among the 30 leading drug companies fell by 50% since 1990. At a 10% rate of return last year,...
Learn More

Deal Watch Annual Review 2011

18th January 2012
The Annual Review of deals by the Medius Deal Watch Team can be accessed through the link below.
Learn More

Viewpoint: Pharma Industry Myths

06th January 2012
Amidst the voluminous commentaries, blogs, tweets, panels and papers about the future of the pharma industry, certain thoughts seem to be becoming articles of faith:
Learn More

Europe's stellar decade of prostate cancer innovation

24th September 2011
If, in 2001, you had hormone resistant metastatic prostate cancer, then your treatment options were severely limited. Nothing could extend your life and the focus was on providing you with...
Learn More

Are we all biotech now?

24th June 2011
The past 25 years has witnessed an unparalleled consolidation of the pharmaceutical industry, and some predict a fate similar to the agchem industry where currently six companies control some 75% of...
Learn More

China: Opportunities for biotech firms

24th March 2011
China is serious about medicine. Universal access to basic healthcare, an improving IP environment, Chinese companies desire for innovation and substantial funding opportunities are opening up...
Learn More

Re-Profiling: a Hidden Threat to Originators?

25th February 2011
As James Black is famously quoted as saying, "the most fruitful basis for the discovery of a new drug is to start with an old drug". This has stimulated a heightened search for new indications for...
Learn More

Mitigating Out-sourcing Risk

29th December 2010
Many firms that outsource major projects can end up managing relationships at arms-length. For complex, business-critical projects, this is a high risk strategy as it may fail to give sufficient...
Learn More
Previous
1 2 3 4
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.